Tandem Expands t:slim X2 Pump Compatibility with Abbott’s Libre 3 Plus Sensor in Five EU Markets
Event summary
- Tandem Diabetes Care has launched compatibility between its t:slim X2 insulin pump and Abbott’s FreeStyle Libre 3 Plus CGM sensor in the UK, Switzerland, Sweden, Finland, and Italy.
- The integration allows real-time glucose data sharing every minute via the Tandem t:slim mobile app.
- Tandem plans to expand availability to Belgium, the Netherlands, and Germany later in 2026.
- Control-IQ+ technology adjusts insulin delivery every five minutes based on predicted glucose values.
The big picture
Tandem’s move to integrate Abbott’s latest CGM sensor underscores the growing trend toward interoperability in diabetes management technology. By offering more choices for continuous glucose monitoring, Tandem aims to strengthen its position in a market increasingly dominated by hybrid closed-loop systems. The expansion into key European markets signals Tandem’s strategic push to capture a larger share of the global insulin pump market.
What we're watching
- Market Expansion
- Whether Tandem can sustain its international rollout pace and meet 2026 targets for additional countries.
- Competitive Positioning
- How this integration affects Tandem’s competitive stance against other diabetes management systems.
- Regulatory Compliance
- The ease with which Tandem navigates varying regulatory landscapes across European markets.
Related topics